sapanisertib   Click here for help

GtoPdb Ligand ID: 7933

Synonyms: INK 128 | INK-128 | INK128 | MLN0128 | TAK-228
PDB Ligand
Compound class: Synthetic organic
Comment: Sapanisertib (INK128) is an ATP-competitive inhibitor of mTOR in mTORC1 and mTORC2 complexes, that exhibits potent anti-tumour activity [1-3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 121.67
Molecular weight 309.13
XLogP 1.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
Isomeric SMILES Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C
InChI InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
InChI Key GYLDXIAOMVERTK-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
INK-128 has has shown broad preclinical anti-tumour activity against a range of solid tumors [4]. Multiple Phase 2 clinical trials have been registered with ClinicalTrials.gov. These include studies in patients with metastatic anaplastic thyroid cancer (NCT02244463), metastatic castration-resistant prostate cancer (NCT02091531), ER/PR+ve/HER2-ve breast cancer (in combination with exemestane or fulvestrant in postmenopausal women; NCT02049957), refractory/unresectable pancreatic neuroendocrine carcinoma (NCT028939300) and relapsed/refractory ALL (NCT02484430). Click here to link to the complete list of sapanisertib/MLN0128/Tak-228/INK-128 clinical trials @ ClinicalTrials.gov.